Russian Journal of ImmunologyRussian Journal of Immunology1028-72212782-7291Russian Society of Immunology2410.31857/S102872210006429-6Research ArticleMYELOID-DERIVED SUPPRESSOR CELLS IN MULTIPLE MYELOMA PATIENTSDURING THE MOBILIZATION OF HEMATOPOETIC STEM CELLSAristovaT. A.<p>postgraduate student,</p><p>Novosibirsk</p>ct_lab@mail.ruBatorovE. V.<p>PhD, Researcher,</p><p>Novosibirsk</p>fake@neicon.ruOstaninA. A.<p>MD, Chief Researcher, </p><p>Novosibirsk</p>fake@neicon.ruFederal Budget Institution of Science «Research Institute of Fundamental and Clinical Immunology»15042019222-11421430304202003042020Copyright © 2019, Aristova T.A., Batorov E.V., Ostanin A.A.2019<p>We investigated the relative content of circulating early (Lin<sup></sup>CD33<sup>+</sup>HLA<sup>-</sup>DRCD66b<sup></sup>), granulocyte (Lin<sup></sup>CD33<sup>+</sup>HLA<sup>-</sup>DRCD66b<sup>+</sup>) and monocyte (CD14<sup>+</sup>HLA<sup>-</sup>DR<sup>low/</sup>) myeloid-derived suppressor cells (MDSCs) in patients with primary multiple myeloma (MM) at the mobilization of hematopoietic stem cells (HSC). The relative count of all the studied subtypes of MDSCs in patients with both complete remission and partial response did not significantly differ from those in healthy donors. Mobilization of HSCs was not associated with any changes in the content of CD14<sup>+</sup>HLA<sup>-</sup>DR<sup>low/</sup> and Lin<sup></sup>CD33<sup>+</sup>HLADRCD66b<sup></sup>, however, led to a significant increase in LinCD33+HLA-DRCD66b+. Thus, carrying out the mobilization of HSCs in patients with MM maybe accompanied by the accumulation of granulocyte MDSCs in the autograft.</p>myeloid-derived suppressor cellsmultiple myelomamobilization of hematopoietic stem cellsмиелоидные супрессорные клеткимножественная миеломамобилизация гемопоэтических стволовых клеток[1. Betsch A., Rutgeerts O., Fevery S., Sprangers B., Verhoef G., Dierickx D., Beckers M. Myeloid-derived suppressor cells in lymphoma: The good, the bad and the ugly.//Blood Rev. 2018. pii: S0268–960X(17)30092–9.][2. Khalifa K. A., Badawy H. M., Radwan W. M., Shehata M. A., Bassuoni M. A. CD14(+) HLA-DR low/(–) monocytes as indicator of disease aggressiveness in B-cell non-Hodgkin lymphoma. Int J Lab Hematol. 2014,36(6), 650–5.][3. Marini O., Spina C., Mimiola E., Cassaro A., Malerba G., Todeschini G., Perbellini O., Scupoli M., Carli G., Facchinelli D., Cassatella M., Scapini P., Tecchio C. Identification of granulocytic myeloid-derived suppressor cells (G-MDSCs) in the peripheral blood of Hodgkin and non-Hodgkin lymphoma patients. Oncotarget. 2016, 7(19), 27676–88.][4. Romano A., Parrinello N. L., Vetro C., Forte S., Chiarenza A., Figuera A., Motta G., Palumbo G. A., Ippolito M., Consoli U., Di Raimondo F. Circulating myeloid-derived suppressor cells correlate with clinical outcome in Hodgkin Lymphoma patients treated up-front with a risk-adapted strategy. Br J Haematol. 2015,168(5), 689–700.]